

MERCK & CO INC  
Form 8-K  
July 30, 2007

---

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported):

July 24, 2007

Merck & Co., Inc.

(Exact name of registrant as specified in its charter)

New Jersey

(State or other jurisdiction  
of incorporation)

1-3305

(Commission  
File Number)

22-1109110

(I.R.S. Employer  
Identification No.)

One Merck Drive, P.O. Box 100, Whitehouse  
Station, New Jersey

(Address of principal executive offices)

08889

(Zip Code)

Registrant's telephone number, including area code:

908-423-1000

Not Applicable

Former name or former address, if changed since last report

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))



**Top of the Form**

**Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.**

On July 24, 2007, the Compensation and Benefits Committee (the "Committee") of Merck & Co., Inc. ("Merck" or the "Company") approved the following changes for Dr. Peter S. Kim, the Company's President, Merck Research Laboratories, effective August 1, 2007:

- An increase in annual base salary to \$1,000,008 (formerly, \$881,496); and
- An increase in target Executive Incentive Plan award to 105 percent (formerly, 100 percent) of base salary.

Mr. Richard T. Clark, the Company's Chairman, President and Chief Executive Officer, recommended the changes to the Committee in recognition of Dr. Kim's significant contributions to Merck, as well as his highly valuable experience and exceptional leadership abilities.

---

**Top of the Form**

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Merck & Co., Inc.

*July 30, 2007*

By: */s/ Debra A. Bollwage*

---

*Name: Debra A. Bollwage*

*Title: Senior Assistant Secretary*